1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 2:The intracranial TI in patients with CTD and the controls
Intracranial TI, median (IQR) P Controls (n = 52) Marfan Syndrome (n = 36) LDS (n = 32) Marfan Syndrome vs Controls LDS vs Controls LDS vs Marfan Syndrome A1 9 (6–12) 11.5 (8–16) 15.5 (11–21) .02 <.001 .02 M1 5 (1–7) 11.5 (6–22) 12.5 (6–21) <.001 <.001 .92 IICA 97 (80.5–110) 123.5 (105–144) 141.5 (123–160.5) <.001 <.001 .06 VBS 12 (9–19) 28.5 (20–36) 52 (32–73.5) <.001 <.001 <.001